Randomized clinical trials with levosimendan

American Journal of Cardiology

Volumn 96, Issue 6 SUPPL., 2005, Pages 74-79

  Mebazaa, Alexandre ^a   Barraud, Damien ^a   Welschbillig, Stéphane ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM SENSITIZER; DOBUTAMINE; INOTROPIC AGENT; LEVOSIMENDAN; PLACEBO; VASODILATOR AGENT;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; CLINICAL TRIAL; DIZZINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HOSPITALIZATION; HUMAN; HYPOTENSION; LUNG CAPILLARY PRESSURE; NAUSEA; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; SYMPTOM;

EID: 25144450441     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.07.024     Document Type: Article

References (25)

1. W. Gattis Stough, C.M. O'Connor, M. Gheorghiade Overview of current noninodilator therapies for acute heart failure syndromes Am J Cardiol 96 suppl 6A 2005 41G 46G
2. M. Bayram, L. De Luca, M.B. Massie, M. Gheorghiade Dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes a reassessment Am J Cardiol 96 suppl 6A 2005 47G 58G
3. M. Gheorghiade, J.R. Teerlink, A. Mebazaa Pharmacology of new agents for acute heart failure syndromes Am J Cardiol 96 suppl 6A 2005 68G 73G
4. M.S. Nieminen, J. Akkila, G. Hasenfuss, F.X. Kleber, L.A. Lehtonen, V. Mitrovic, O. Nyquist, W.J. Remme Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure J Am Coll Cardiol 36 2000 1903 1912
5. M.T. Slawsky, W.S. Colucci, S.S. Gottlieb, B.H. Greenberg, E. Haeusslein, J. Hare, S. Hutchins, C.V. Leier, T.H. LeJemtel, E. Loh Study Investigators Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure Circulation 102 2000 2222 2227
6. V.S. Moiseyev, P. Poder, N. Andrejevs, M.Y. Ruda, A.P. Golikov, L.B. Lazebnik, Z.D. Kobalava, L.A. Lehtonen, T. Laine, M.S. Nieminen, K.I. Lie RUSSLAN Study Investigators Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction a randomized, placebo-controlled, double-blind study (RUSSLAN) Eur Heart J 23 2002 1422 1432
7. F. Follath, J.G. Cleland, H. Just, J.G. Papp, H. Scholz, K. Peuhkurinen, V.P. Harjola, V. Mitrovic, M. Abdalla, E.P. Sandell, L. Lehtonen Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study) a randomised double-blind trial Lancet 360 2002 196 202
8. M.N. Zairis, C. Apostolatos, F. Anastassiadis, N. Kouris, H. Grassos, M. Sifaki, D. Babalis, S. Foussas Comparison of the effect of levosimendan, or dobutamine or placebo in chronic low output decompensated heart failure Calcium Sensitizer or Inotrope or NOne in Low Output Heart Failure (CASINO) Study In Program and abstracts of the European Society of Cardiology, Heart Failure Update 2004; June 12-15 2004 Wroclaw, Poland. Abstract 273
9. A. Mebazaa, A. Cohen-Solal, F. Kleber, M. Nieminen, M. Packer, S. Pocock, P. Põder, T. Sarapohja, M. Kivikko Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure Program and abstracts of the 8th Annual Scientific Meeting of the Heart Failure Society of America 2004 September 12-15, 2004; Toronto, Ontario, Canada. Abstract 231
10. M. Packer, W.S. Colucci, L. Fisher, B.M. Massie, J.R. Teerlink, J.B. Young, C.J. Garratt Development of a comprehensive new end point for the evaluation of new treatments for acute decompensated heart failure results with levosimendan in the REVIVE-1 study [abstract] J Card Fail 9 2003 S61
11. J. Lilleberg, V. Ylonen, L. Lehtonen, L. Toivonen The calcium sensitizer levosimendan and cardiac arrhythmias an analysis of the safety database of heart failure treatment studies Scand Cardiovasc J 38 2004 80 84
12. A.P. Coletta, J.G. Cleland, N. Freemantle, A.L. Clark Clinical trials update from the European Society of Cardiology Heart Failure meeting SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy Eur J Heart Fail 6 2004 673 676
13. S. Johansson, M. Apajasalo, T. Sarapohja, C. Garratt Effect of levosimendan treatment on length of hospital and intensive care stay in the REVIVE I study [abstract] Crit Care 8 suppl 1 2004 P88
14. H. Yasue, M. Yoshimura, H. Sumida, K. Kikuta, K. Kugiyama, M. Jougasaki, H. Ogawa, K. Okumura, M. Mukoyama, K. Nakao Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure Circulation 90 1994 195 203
15. N. Hama, H. Itoh, G. Shirakami, O. Nakagawa, S. Suga, Y. Ogawa, I. Masuda, K. Nakanishi, T. Yoshimasa, Y. Hashimoto Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction Circulation 92 1995 1558 1564
16. S. Wiese, T. Breyer, A. Dragu, R. Wakili, T. Burkard, S. Schmidt-Schweda, E.M. Fuchtbauer, U. Dohrmann, F. Beyersdorf, D. Radicke, C.J. Holubarsch Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium influence of angiotensin II and diastolic fiber length Circulation 102 2000 3074 3079
17. M. Davis, E. Espiner, G. Richards, J. Billings, I. Town, A. Neill, C. Drennan, M. Richards, J. Turner, T. Yandle Plasma brain natriuretic peptide in assessment of acute dyspnoea Lancet 343 1994 440 444
18. T.A. McDonagh, S.D. Robb, D.R. Murdoch, J.J. Morton, I. Ford, C.E. Morrison, H. Tunstall-Pedoe, J.J. McMurray, H.J. Dargie Biochemical detection of left-ventricular systolic dysfunction Lancet 351 1998 9 13
19. Q. Dao, P. Krishnaswamy, R. Kazanegra, A. Harrison, R. Amirnovin, L. Lenert, P. Clopton, J. Alberto, P. Hlavin, A.S. Maisel Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting J Am Coll Cardiol 37 2001 379 385
20. P.A. McCullough, R.M. Nowak, J. McCord, J.E. Hollander, H.C. Herrmann, P.G. Steg, P. Duc, A. Westheim, T. Omland, C.W. Knudsen B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure analysis from Breathing Not Properly (BNP) Multinational Study Circulation 106 2002 416 422
21. S. Kyrzopoulos, S. Adamopoulos, J.T. Parissis, J. Rassias, G. Kostakis, E. Iliodromitis, D. Degiannis, D.T. Kremastinos Levosimendan reduces plasma B-type natriuretic peptide and interleukin-6, and improves central hemodynamics in severe heart failure patients Int J Cardiol 99 2005 409 413
22. E.P. Sandell, E. Wesby-van Swaay, P. Põder, T. Sarapohja, M. Nieminen, L. Lehtonen A meta-analysis on the safety of the calcium sensitizing agent levosimendan Presented at the Heart Failure Update Meeting (European Society of Cardiology) 2004 June 12-15, 2004; Wroclaw, Poland
23. Simdax [package insert] 2001 Orion Corporation Espoo, Finland
24. M. Nieminen, F. Follath, V.S. Moiseyev, V.-P. Harjola, E.P. Sandell Efficacy and safety profile of levosimendan in male and female patients Presented at the Heart Failure Update Meeting (European Society of Cardiology) 2004 June 12-15, 2004; Wroclaw, Poland
25. S. Sonntag, S. Sundberg, L.A. Lehtonen, F.X. Kleber The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia J Am Coll Cardiol 43 2004 2177 2182